Difference between revisions of "Post-transplant lymphoproliferative disorder"
Jump to navigation
Jump to search
(→IHC) |
|||
| Line 18: | Line 18: | ||
==IHC== | ==IHC== | ||
*B cell markers +ve. | *B cell markers +ve. | ||
*EBER diffusely +ve. | *[[EBER]] diffusely +ve. | ||
==See also== | ==See also== | ||
Latest revision as of 19:56, 26 December 2019
Post-transplant lymphoproliferative disorder, abbreviated PTLD, is something afflicts people that had transplants (solid organ and bone marrow). It is essentially a type of B-cell lymphoma.
General
- Rare.
- B cell neoplasm associated with EBV.[1][2]
- May develop from a clinically latent EBV infection that is detectable by the presence of "passenger cells" = scattered EBER positive lymphocytes.[3]
- Commonly in the GI tract as it gets the most immunosuppression; immunosuppressives are taken orally -- not cleaned by the liver prior to reaching the GI tract.
Microscopic
Features:
- Similar to large cell lymphomas:
- Large lymphoid cells with a diameter ~2x a resting lymphocyte.
- Nucleoli.
DDx:
IHC
- B cell markers +ve.
- EBER diffusely +ve.
See also
- Diffuse large B cell lymphoma (DLBCL).
- Heart transplant pathology.
- Lung transplant pathology.
- Lymphoproliferative disorder.
References
- ↑ URL: http://emedicine.medscape.com/article/431364-overview. Accessed on: 10 February 2011.
- ↑ Gottschalk S, Rooney CM, Heslop HE (2005). "Post-transplant lymphoproliferative disorders". Annu. Rev. Med. 56: 29–44. doi:10.1146/annurev.med.56.082103.104727. PMID 15660500.
- ↑ URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422031/. Accessed on: 3 March 2011.